Previous 10 | Next 10 |
London, UK, April 27, 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the launch of a proposed public offering of 4,00...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips MindMed (NASDAQ: MNMD ) stock isn’t doing so hot with shares taking a beating on the first day of trading at their new home. Source: local_doctor / Shutterstock.com MNMD stock joined the Nasdaq Exchang...
Diabetes is one of the most alarming issues all over the world. At the moment, nearly 463 million patients are dealing with it. By 2045, that number could explode to approx. 700 million, according to the International Diabetes Foundation. On top of that, millions more are pre-diabetic and a...
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Big Tech rolls inThe next round of Big Tech earnings is coinciding with a milestone for the Nasdaq Composite, which has returned to record levels for the f...
New York-based MindMed will begin trading on the Nasdaq today, becoming the second psychedelic company ever to go public on a major American exchange. Shroom drug developer Compass Pathways (CMPS) debuted only six months ago, while another "drug growth platform,"called Atai Life Sciences, fil...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Monday trading may be over, but make sure you are all caught up and ready for the week. To start, what did the stock market do today? And what else should be on your radar? Source: Shutterstock The S&P 500 c...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips What Happened to the COMPASS Pathways Stock Price Today? Source: Shutterstock Shares of psychedelics-inspired medicine developer COMPASS Pathways (NASDAQ: CMPS ) jumped more than 5% on Monday, continuing wha...
A new study led by the Imperial College London’s Centre for Psychedelic Research has yielded promising results for the use of psilocybin in psychiatric therapy. Psilocybin, the psychoactive compound of magic mushrooms – was pitted up against popular SSRI (selective ser...
The psychedelics investment proposition is an enticing one for investors, and the bedrock of the industry is the potential attached to clinical research on psychedelic substances. Thanks to the groundbreaking progress of studies and trials evaluating psychedelic treatments, the enti...
Palm Beach, FL – April 22, 2021 – Global Psychedelic and Psilocybin Drugs market is growing rapidly due to the increasing number of depression cases and rising special designation from the regulatory authorities to the company to expedite the development process of medicines. ...
News, Short Squeeze, Breakout and More Instantly...
2024-08-01 23:30:19 ET Image source: The Motley Fool. Compass Pathways Plc (NASDAQ: CMPS) Q2 2024 Earnings Call Aug 01, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: Compass Pathways Plc (CMPS) Q2 2024 Earnings Call Tr...
Top-line COMP005 data for COMP360 phase 3 pivotal program in treatment-resistant depression expected in fourth quarter 2024 Gino Santini to join Board of Directors as Chairman Lori Englebert named new Chief Commercial Officer Cash position of $228.6 million ...
LONDON, July 24, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the second quarter 2024 ending June 30, 2024, a...